[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-dependence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-dependence":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,69,92,120,161,195,222,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125",false,"NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","ALL","14 Years","17 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Cannabis Use","Cannabis Dependence","Cannabis Use Disorder","Cannabis Abuse","Cannabis Intoxication","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[55,38,46],"Cannabis","RECRUITING","2026-06-18",{"date":59,"type":60},"2026-06-22","ACTUAL",{"date":62,"type":60},"2026-06-15",{"date":64,"type":22},"2030-05-01",{"name":66,"class":67},"Indiana University","OTHER",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":68},"100541757","early-phase-1-evaluating-the-delivery-and-effects-of-thc-vaping-liquids-in-the-bloodstream-100541757","NCT06334016","Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream","Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study","Inclusion Criteria:\n\n* Age ≥ 21 years of age; (self-reported on screening, verified at study visit).\n* Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).\n* Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).\n* Report use of THC vaping liquids at least weekly (4x\u002Fmonth); (self-reported).\n* Daily use of nicotine vaping products containing 5% nicotine for at least 3 months prior to enrollment; (self-reported).\n* Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products\u002Fprocedures.\n* Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.\n* Negative THC saliva test (NarcoCheck Ref#: NCE-S-THC-1), detection level 1-3 on urinary THCA rapid test (NarcoCheck® THC PreDosage), and illicit drug screen negative for all drugs except THC (NarcoCheck® Évolutive®).\n* Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 7 days prior to each session.\n* Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Detection level 4-5 (\\> 300 ng\u002FmL) on urinary THCA rapid test (NarcoCheck® THC PreDosage Ref#: DOA-M03-9B) and a positive result on THC saliva test (NarcoCheck Ref#: NCE-S-THC-1).\n* Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted\n* Illegal or non-prescription drug use\u002Falcohol substance use disorder (SUD) within the past year; (self-reported).\n* Report 2 or more drinking occasions\u002Fweek with 4 or more drinks\u002Foccasion; (self-reported).\n* Report of daily cigarette use; (self-reported).\n* Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).\n* Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported).\n* Current or prior cancer diagnosis.\n* Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).\n* Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).\n* Unwilling or unable to follow protocol requirements.\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.\n* The following special populations will be excluded:\n\n  * Cognitively impaired adults\u002Fadults with impaired decision-making capacity\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Pregnant women\n  * Prisoners\n* No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.",true,"21 Years",{"count":79,"type":22},60,[81],"EARLY_PHASE1","This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.",[29],"NOT_YET_RECRUITING",{"date":59,"type":60},{"date":87,"type":22},"2026-07-15",{"date":89,"type":22},"2028-03-01",{"name":91,"class":67},"Roswell Park Cancer Institute",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":76,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":68},"100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","16 Years","80 Years",{"count":102,"type":22},134,[25],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[106,30,29,28,107,108,109,110],"Psychotic Disorders","Schizophrenia; Psychosis","Cognitive Dysfunction","Memory Impairment","Neuroimaging","2026-05-19",{"date":113,"type":60},"2026-05-22",{"date":115,"type":60},"2022-04-21",{"date":117,"type":22},"2027-05",{"name":119,"class":67},"Douglas Mental Health University Institute",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":68},"100633203","phase-2-effect-of-semaglutide-on-cannabis-use-in-adults-with-cannabis-use-disorder-100633203","NCT07523633","Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder","A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder","HASHTAG","Inclusion Criteria:\n\n1. Informed oral and written consent.\n2. Meets the criteria for cannabis use disorder (CUD) according to DSM-5 or ICD-10.\n3. Currently seeking to cut down or stop cannabis use.\n4. Positive urine test for cannabinoids.\n5. Body mass index (BMI) ≥ 23 kg\u002Fm².\n6. Age 18-70 years.\n7. Recent frequent cannabis use, defined as use on ≥16 days out of the past 28 days.\n8. Cannabis use (smoked, vaped, edibles) equivalent to THC doses of ≥14 grams in the past 28 days before baseline.\n9. Ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Currently meeting non-cannabis\u002Ftobacco substance use disorder (ICD-10 or DSM-5).\n2. Current or past diagnosis of severe psychiatric illness, defined as schizophrenia, bipolar disorder, or other psychoses, within the past five years.\n3. Suicide attempt or suicidal behavior within the past five years.\n4. Severe neurological disorders, including previous severe traumatic brain injury, stroke, or intracranial hemorrhage.\n5. Type 1 diabetes and type 2 diabetes.\n6. Pregnant or potentially pregnant women: Women of childbearing potential (WOCBP) who are pregnant, breastfeeding, planning to become pregnant within the next eight months (including 20 weeks of treatment plus two months after discontinuation of semaglutide), or not using effective contraception throughout the study period. Effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, implant, injection), intrauterine device\u002Fsystem (IUD\u002FIUS), bilateral tubal occlusion, partner with vasectomy, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level \\>3 U\u002FL at inclusion will also be excluded.\n7. Impaired liver function (liver transaminases \\>3 times the upper reference limit)\n8. Impaired renal function (eGFR \\\u003C50 ml\u002Fmin and\u002For plasma creatinine \\>150 µmol\u002FL).\n9. Impaired pancreatic function (past or current acute or chronic pancreatitis and\u002For amylase \\>2 times the upper limit).\n10. History of medullary thyroid carcinoma (MTC) and\u002For family history of MTC and\u002For Multiple Endocrine Neoplasia type 2 (MEN 2).\n11. Heart disease is defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris, and\u002For myocardial infarction within the past 12 months.\n12. Uncontrolled hypertension (systolic blood pressure \\>180 mmHg, diastolic blood pressure \\>110 mmHg).\n13. Receipt of experimental medication within the past 30 days.\n14. Use of weight-loss medication within the past 3 months.\n15. Hypersensitivity to the active substance or any of the excipients.\n16. For patients undergoing brain scanning only:\n\n    Contraindications to MRI scanning (magnetic implants, pacemaker, claustrophobia, etc.).\n17. Inability to speak and\u002For understand Danish.\n18. Other conditions: Any other condition that, in the investigator's opinion, may interfere with participation in the trial.","18 Years","70 Years",{"count":131,"type":22},100,[133],"PHASE2","The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.",[30,136,31,29,137],"Cannabis Use Disorders","Cannabis Addiction",[139,140,141,142,143,144,145,146,147,110,148,149,150,151],"GLP-1","Glucagon-like peptide 1","semaglutide","fMRI","cannabis","GLP-1 receptor agonist","Randomized Controlled Trial","Double-Blind Method","Placebo-Controlled","Brain activity","Cue reactivity","Craving","Drug therapy","2026-05-12",{"date":154,"type":60},"2026-05-14",{"date":156,"type":60},"2026-04-30",{"date":158,"type":22},"2028-04-30",{"name":160,"class":67},"Anders Fink-Jensen, MD, DMSci",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":76,"sex":168,"minAge":128,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":180,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":68},"100188602","imaging-cannabinoid-receptors-using-positron-emission-tomography-pet-scanning-100188602","NCT01730781","Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning","Characterization of CB1 Receptors Using [11-C]OMAR","Inclusion Criteria:\n\n* Males ages 18-55\n* For cannabis users:\n* Willing to abstain from cannabis use for four weeks\n* For schizophrenia:\n* Meets DSM-IV-TR criteria for schizophrenia or schizoaffective disorder\n* For prodrome for psychotic illness:\n* Meets SIPS criteria for prodromal syndrome\n* For family history positive:\n* First degree relative with alcoholism\n* For Post-Traumatic Stress Disorder\n* Meets DSM-IV-TR criteria for PTSD\n* For OUD\n* Meets DSM-IV-TR criteria for Opioid Use Disorder\n\nExclusion Criteria:\n\n* Current neuro-psychiatric illness (including cannabis dependence) or severe systemic disease. Cannabis use disorder is permitted in the cannabis dependent group. Schizophrenia and schizoaffective disorder is permitted in the schizophrenia group. Psychotic symptoms are permitted in the prodromal group. Post-Traumatic Stress Disorder is permitted in the PTSD group and Opioid Use Disorder is permitted in the OUD group.\n* Presence of ferromagnetic metal in the body or heart pacemaker\n* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits\n* Are claustrophobic","MALE","55 Years",{"count":131,"type":22},"OBSERVATIONAL","The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, \\[11C\\]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available.\n\nThose in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia.",[174,29,175,176,177,178,179],"Schizophrenia","Prodromal for Psychotic Illness","Family History of Alcoholism","Healthy Control","Opioid-use Disorder","Post Traumatic Stress Disorder",[181,182,174,183,184,185],"Cannabis dependence","Brain Imaging","Control","PTSD","OUD","2026-04-23",{"date":188,"type":60},"2026-04-27",{"date":190,"type":4},"2010-07",{"date":192,"type":22},"2026-12",{"name":194,"class":67},"Yale University",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":202,"maxAge":128,"enrollmentInfo":203,"targetDuration":205,"studyType":171,"phases":4,"briefSummary":199,"conditions":206,"keywords":209,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":68},"100605256","cannabis-abstinence-and-neurocognitive-assessment-in-adolescence-100605256","NCT07160153","Cannabis Abstinence and Neurocognitive Assessment in Adolescence","CANAA","Inclusion Criteria:\n\n* Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.\n\nExclusion Criteria:\n\n* psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.\n* somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.\n* Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.","15 Years",{"count":204,"type":22},29,"2 Months",[29,207,208],"Harmful Use","Cognitive Assessment",[29,30,210,211,212],"Abstinence","Cognitive Function","Disorder; Abstinence; Cognitive Function; Neuropsychological","2025-09-15",{"date":215,"type":60},"2025-09-19",{"date":217,"type":60},"2024-12-03",{"date":219,"type":22},"2029-08-31",{"name":221,"class":67},"University Hospital Pilsen",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":68},"100599961","exercise-intervention-as-treatment-for-people-using-cannabis-exit-c-100599961","NCT07091292","Exercise Intervention as Treatment for People Using Cannabis (ExIT-C)","Exercise Intervention as Treatment for People Using Cannabis (ExIT-C)-a Randomized Controlled Trial to Investigate the Effectiveness of Aerobic Exercise on Cannabis Dependence and Use Disorder","ExIT-C","Inclusion Criteria:\n\n* Young adults of 18-40 years old\n* Able to read and communicate in English and\u002For Chinese\n* Able to give informed consent\n* Using cannabis or marijuana as the primary psychoactive substance of abuse\n* Suffering from cannabis addiction, defined by:\n\n  i. Cannabis Dependence with an SDS score ≥ 3, or ii. Cannabis Use Disorder according to the Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5), or iii. Cannabis Harmful Use or Dependence according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) or Clinical descriptions and diagnostic requirements for International Classification of Diseases 11th Revision (ICD-11) mental, behavioral, and neurodevelopmental disorders.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 40 years old\n* Unable to read English or Chinese\n* Unable to give informed consent\n* Absolute and\u002For relative contraindications to exercise training as indicated by the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and the electronic Physical Activity Readiness Medical Examination (ePARmed-X+)\n* Had been diagnosed with the following disorders, including:\n\n  i. Neurodevelopmental Disorders DSM-5: Intellectual Disabilities, Communication Disorders, Specific Learning Disorder, Autism Spectrum Disorder and Motor Disorders ICD-11: Disorders of intellectual development (6A00), Developmental speech or language disorders (6A01), Autism spectrum disorder (6A02), Developmental learning disorder (6A03), Developmental motor coordination disorder (6A04), Stereotyped movement disorder (6A06), Primary tics or tic disorders (8A05.0) ii. Other DSM-5 defined Substance Use Disorder greater than mild in severity (i.e., severity score ≥ 2), except for tobacco or caffeine iii. Neurocognitive Disorders (DSM-5, or ICD-11 6D70-72 \\& 6D80-86)","40 Years",{"count":79,"type":22},[25],"In Hong Kong, although the total number of drug abusers is trending down in recent years, the number of cannabis users continues to surge. The misuse of cannabis, if left unattended, predisposes various degrees of dependence and use disorders, which could later on induce psychotic disorders and schizophrenia. Effective strategies combating cannabis dependence and cannabis use disorder (CUD) are therefore warranted.\n\nExercise presents as a low-cost and low-stigma alternative to traditional pharmacotherapy and psychotherapy in the treatment of substance use disorders, which also promotes physical well-being with virtually no side effects. While exercise has some success in treating use disorders of stimulants, alcohol, and tobacco, evidence of its effects on CUD remains scarce. Hence, the present study will be conducted to assess the effectiveness of a 12-week aerobic exercise training regimen on reducing cannabis dependence and the severity of CUD.\n\nParticipants with cannabis dependence will be randomly assigned to either the exercise or the control group. Participants assigned to the exercise group will partake in a 12-week aerobic exercise training program of vigorous-intensity using indoor bikes, whereas those assigned to the control group will perform sham exercise of very light-intensity on indoor bikes. The 12-week study is divided into three (3) 4-week phases:\n\n1. Intensive Intervention - all participants will exercise twice a week under supervision.\n2. Active Intervention - all participants will exercise once a week under supervision.\n3. Passive Maintenance - no supervised exercise sessions will be provided. All participants will receive exercise reminders via weekly text messages.\n\nCannabis use-related, cognitive, and physical outcomes will be assessed every 4 weeks, whereas withdrawal symptoms will be assessed and urine quick test administered every week.",[31,29,30],[236,143,237,238,239],"exercise","cannabis use disorder","cannabis dependence","substance abuse","2025-07-21",{"date":242,"type":60},"2025-07-29",{"date":244,"type":60},"2025-07-02",{"date":246,"type":22},"2028-12",{"name":248,"class":67},"The University of Hong Kong",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":278},"100572478","a-mobile-app-to-reduce-andor-quit-cannabis-use-100572478","NCT06733792","A Mobile App to Reduce and\u002For Quit Cannabis Use","Efficacy of a Digitalized Selective Prevention Program (App - \"CANQUIT\") to Reduce and\u002For Quit Cannabis Use","CANQUIT","Inclusion Criteria:\n\n* Between 18 and 30 years old.\n* At least one occasion of cannabis use in the last month.\n* Access to smartphones (iOS or Android).\n* Access to Internet.\n\nExclusion Criteria:\n\n\\-","30 Years",{"count":259,"type":22},120,[25],"This study aims to develop an App-based intervention (CANQUIT) aimed at regular cannabis users. The efficacy of this intervention will be evaluated in the short-term (1-month follow-up) and long-term (3- and 6-months follow-ups) using a sample of 120 participants. Participants will be randomly assigned to the experimental arm (App-assisted CBT-based intervention) or the control (App-assisted self-help guide). The study will also estimate the economic impact of the intervention by considering the benefit-cost ratio (BCR) and net benefit (in €) associated with the total cost of the program. The goal is to provide evidence that can inform policy decisions regarding cannabis use and minimize the negative consequences on the physical and mental health of young adults in Spain. This study aims to offer a cost-effective prevention strategy that minimize the negative consequences on the physical and mental health of young adults in Spain.",[29],[55,264,265,266,267,268],"App-based intervention","Young adults","Selective prevention","CBT","Contingency Management","2025-03-25",{"date":271,"type":60},"2025-03-30",{"date":273,"type":60},"2024-12-13",{"date":275,"type":22},"2027-03",{"name":277,"class":67},"Alba González-Roz, PhD",2]